26/08/2025
LemnaRed®Pharmaceutical-Grade Astaxanthin
▲ Supporting FDA 505(b)(2) Regulatory Pathway for Drug Development
■ Produced via a precision fermentation platform, compliant with CMC manufacturing requirements
■ Single stereoisomer [3S,3’S] with a defined pharmacological mechanism of action
■ Completed GLP-compliant toxicology study (NOAEL = 750 mg/kg/day), fulfilling preclinical safety requirements
▲ Potential Therapeutic Indications
■ Non-Alcoholic Fatty Liver Disease (NAFLD / NASH)
■ Hyperlipidemia and Metabolic Syndrome
■ Rare Premature Aging Disorders (Werner Syndrome, Hutchinson-Gilford Progeria Syndrome)
■ Age-Related Macular Degeneration (AMD) & Retinopathy
■ Polycystic O***y Syndrome (PCOS)
■ Others: Mild Cognitive Impairment & Early-Stage Alzheimer’s Disease,
Prediabetes / Insulin Resistance, Sarcopenia & Geriatric Exercise Recovery
®Pharmaceutical-Grade Astaxanthin(API)
®Registered Trademark only be used after authorization.
®is a trademark of Lemnaceae Fermentation, Inc. All Rights Reserved.